NerveCare™

Unique Properties

Patient One NerveCare™ provides a synergistic blend of bioavailable, natural compounds designed to support healthy glucose metabolism along with the health of the nervous system. NerveCare works on virtually all components of the nervous system, from tissue health to circulation and maintenance, and helps defend against diabetic-related concerns.

 

Key Ingredients

Alpha Lipoic Acid (ALA) is a fat- and water-soluble nutrient with antioxidant activity that supports a variety of beneficial effects within the body. ALA plays a role in fighting oxidative stress and free radical formation. Studies support that alpha lipoic acid may positively influence glucose metabolism. ALA has been studied for its ability to improve circulation, particularly in the nervous system. Placebo-controlled clinical trials have shown oral administration of ALA to help relieve sensations of burning. 

 

Acetyl-L-Carnitine (ALC) works synergistically with ALA to enhance antioxidant effects. Research has shown that ALC promotes nerve and cardiovascular health by supporting metabolism and boosting energy production within the cells’ mitochondria. This compound supports the integrity of the nervous system and has been studied for its free radical fighting power in the brain. Carnitine supplementation may help replenish carnitine deficiency, improve insulin resistance, allow cells to use glucose more efficiently, and support regeneration of damaged nerve fibers.

 

Methylcobalamin is a methylated derivative of Vitamin B12 that has been studied in conjunction with Acetyl-L-Carnitine for their combined effects on nerves. Methylcobalamin helps the body metabolize homocysteine, a function vital for nervous system health.

 

Benfotiamine is a fat-soluble, more readily absorbed form of Vitamin B1 (compared to the more common water-soluble form of B1, thiamine). Benfotiamine has a unique open-ring structure that enables benfotiamine to pass directly through cell membranes into the cell. This molecule works through a novel biochemical pathway to support peripheral nerve health and maintain nervous system tissue.

 

 

Research

• In a randomized, double-blind placebo controlled study, participants with nervous system concerns were provided Acetyl-L-Carnitine and methylcobalamin for 24 weeks. Results showed a significant improvement in a majority of symptoms with a high level of tolerability.2
• In another double-blind placebo-controlled study, 181 participants with nervous system concerns were provided low and high doses of benfotiamine. Within 6 weeks, participants reported a significant improvement in their quality of life.5

References

1. Garcia-Alcala, H., et al. Treatment with ?-Lipoic Acid over 16 Weeks in Type 2 Diabetic Patients with Symptomatic Polyneuropathy Who Responded to Initial 4-Week High-Dose Loading. J Diabetes Res. 2015;2015:189857.
2. Li, S., et al. Effects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double-blind, controlled trial. J Diabetes Investig. 2016 Sep;7(5):777-85.
3. Ruhnau K.J., et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med. 1999 Dec;16(12):1040-3.
4. Sima, A.A., et al. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care. 2005 Jan;28(1):89-94.
5. Stracke, H., et al. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes. 2008 Nov;116(10):600-5.
6. Winkler G, Pál B, Nagybéganyi E, et al. Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy. Arzneimittelforschung. 1999 Mar;49(3):220-24.
7. Ziegler, D., et al. Predictors of improvement and progression of diabetic polyneuropathy following treatment with a-lipoic acid for 4 years in the NATHAN 1 trial. J Diabetes Complications. 2016 Mar;30(2):350-6.
8. Ziegler, D., et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006 Nov;29(11):2365-70.